Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomics analyses by iMPAQT in sunitinib resistant cells and its HIF2a knock out cells

ABSTRACT: This analysis was performed among 786-o renal cell carcinoma cell line, its sunitinib resistant cell, and sunitinib resistant Hif2a knock out cell.

ORGANISM(S): Homo Sapiens (human)

SUBMITTER: Hirofumi Yoshino

PROVIDER: PXD007222 | JPOST Repository | Wed Aug 09 00:00:00 BST 2017

REPOSITORIES: jPOST

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	1-cellmix-1.wiff	Wiff
	1-cellmix-1.wiff.scan	Wiff
	2-786-o-test.wiff	Wiff
	2-786-o-test.wiff.scan	Wiff
	3-786-o-rediSni.wiff	Wiff

Items per page:

1 - 5 of 9

Similar Datasets

Increased HRD score in cisplatin resistant penile cancer cells

Project description:HRD Score was generated from a penile carcinoma cell line resistant to 5FU and CDDP as well as cross resistant cell line.

2023-11-17 | GSE218782 | GEO

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)

Project description:This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications. New recruitment is open for all active cohorts. Active cohorts: Escalation revised dosing regimen cohort. Closed cohorts: Non-small cell lung cancer (NSCLC, first line), NSCLC (post-platinum), metastatic breast cancer (MBC), colorectal cancer (CRC), urothelial carcinoma (secondary), mesothelioma, gastric/GEJ cancer (first line switch maintenance and second line), and ovarian cancer (secondary and platinum refractory + liposomal doxorubicin), renal cell carcinoma (second line) melanoma and head, neck squamous cell carcinoma (HNSCC), castrate-resistant prostate cancer (CRPC), adrenocortical carcinoma (ACC) urothelial carcinoma (efficacy), gastric/gastroesophageal junction (GEJ) cancer (third line), renal cell carcinoma (RCC, first line) and escalation phase .

| 2138571 | ecrin-mdr-crc

Nonclinical in-vitro evaluation of the transcriptomic and metabolic effects of immune checkpoint inhibitors on sunitinib-resistant renal cell carcinoma

Project description:Recently, immune checkpoint inhibitors (ICIs) have been approved as first line and second-line therapies for individuals with advanced renal cell carcinoma (RCC) who developed a resistance to anti-angiogenic therapies. It remains unknown how ICIs efficacy is affected by the development of resistance to anti-angiogenic inhibitors. Thus, our goal is to evaluate transcriptomic and metabolic effects after ICI therapy of sunitinib-resistant RCC and compare the efficacy of ICIs between naïve and sunitinib-resistant RCC.

2025-01-01 | GSE216495 | GEO

Effect of FOXA1 knockdown on gene expression in sulfasalazine-resistant OSC19SSZR cells

Project description:High-throughput sequencing was performed to analyze genes regulated by the transcription factor FOXA1 in OSC19SSZR cells, a sulfasalazine-resistant oral squamous cell carcinoma cell line.

2023-09-15 | GSE241108 | GEO

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics

Project description:The tyrosine kinase inhibitor sunitinib is an effective first-line treatment for patients with advanced renal cell carcinoma (RCC). Hypothesizing that a functional read-out by mass spectrometry-based (phospho, p-)proteomics will identify predictive biomarkers for treatment outcome of sunitinib, tumor tissues of 26 RCC patients were analyzed. Eight patients were primary resistant (RES) and 18 sensitive (SENS).

2024-01-26 | PXD043514 | Pride

Gene expression profiling of generated sunitinib-resistant RCC cell lines

Project description:The clinical response to sunitinib in advanced renal-cell carcinoma (RCC) is frequently limited in magnitude and duration due to drug resistance, but the underlying mechanisms remain elusive. To discover mechanisms of resistance, we developed drug-resistant cell lines and have their gene expressions profiled and compared. Results provide insight into the molecular mechanisms underlying sunitinib-resistance.

2016-09-30 | GSE69535 | GEO

Label-free quantitative phosphoproteomics of sunitinib-resistant renal cell carcinoma upon estrogen treatment

Project description:Sunitinib is a TKI inhibitor used for managing metastatic renal cell carcinoma (RCC). However, chronic sunitinib treatment in RCC usually results in the development of drug resistance via alternating phosphorylation dynamics. On the other hand, 17-beta-estradiol, or estrogen, has been demonstrated to repress RCC growth partly through regulating cell signallings. To investigate how estrogen can repress sunibitinib-resistant RCC growth and its the possible mechanism of action related protein phosphorylation, a label-free quantitative phosphoproteomics study is performed.

2020-08-07 | PXD011020 | Pride

Gene expression analysis of parental and sulfasalazine-resistant human oral squamous carcinoma cell line OSC19

Project description:To identify the genes involving in the resistance to xCT inhibitors, we established the sulfasalazine-resistant clone of an oral squamous cell carcinoma OSC19 cell line, and the resulting sulfasalazine-resistant cells and its parental cells were subjected to cDNA microarray analysis.

2018-05-01 | GSE113860 | GEO

Exometabolomics of HK2, 786-O cells cultured in Plasmax media

Project description:The objective of this study is to analyse the exometabolomics of human epithelial renal cell line HK2 and clear cell renal cell carcinoma (ccRCC) cell lines 786-O, 786-M1A, 786-M2A, OS-RC-2, OS-LM1 and RFX-631 that are cultured with the Plasmax media. This is part 3 of the study, and the experimental number is MS51.

2022-07-15 | ST002226 | MetabolomicsWorkbench

Gene expression profiling of 786-O cells with ZHX2 and p65 knockdown

Project description:We are examining the regulatory pathway of ZHX2 and p65 in clear cell renal cell carcinoma cell line 786-O

2018-06-30 | GSE110094 | GEO